1. Home
  2. CHNR vs JAGX Comparison

CHNR vs JAGX Comparison

Compare CHNR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Natural Resources Inc.

CHNR

China Natural Resources Inc.

HOLD

Current Price

$3.95

Market Cap

4.9M

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

BUY

Current Price

$7.62

Market Cap

4.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CHNR
JAGX
Founded
N/A
2013
Country
China
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.9M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
CHNR
JAGX
Price
$3.95
$7.62
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $60.00
AVG Volume (30 Days)
3.8K
★ 1.9M
Earning Date
05-15-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.42
EPS
★ N/A
N/A
Revenue
N/A
★ $11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.18
$0.20
52 Week High
$8.20
$41.53

Technical Indicators

Market Signals
Indicator
CHNR
JAGX
Relative Strength Index (RSI) 58.39 53.17
Support Level $3.93 $0.89
Resistance Level $4.13 $8.00
Average True Range (ATR) 0.18 4.25
MACD 0.01 0.96
Stochastic Oscillator 75.61 18.05

Price Performance

Historical Comparison
CHNR
JAGX

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: